Every 8-K that Celldex Therapeutics Inc (CLDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDX filings page.
Celldex Therapeutics, Inc. states that on August 6, 2026 it issued a press release announcing its financial results for the second quarter of 2026. The press release is provided as Exhibit 99.1 and is treated as information that is furnished, rather than filed, under the Exchange Act, limiting its treatment under Section 18 and other liability provisions.
The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. Any future use of the press release in Securities Act or Exchange Act reports will occur only if specifically incorporated by reference.
Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027. Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017.
The company has begun a search for a new Chief Financial Officer. To support continuity, Martin intends to continue serving as CFO through March 31, 2027, or until an appointed successor begins serving in that role, to help ensure a smooth transition of his responsibilities.
Celldex Therapeutics, Inc. reported results from its 2026 annual stockholder meeting, including approval of an amendment to its 2021 Omnibus Equity Incentive Plan. Stockholders increased the shares available for issuance under the plan by 3,400,000, bringing the total reserve to 12,900,000 shares and clarified tax withholding terms for awards.
All director nominees were elected with more than 59 million votes cast in favor for each seat. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 and approved, on an advisory, non-binding basis, the compensation of named executive officers.
Celldex Therapeutics reported a larger net loss for the first quarter of 2026 as it accelerated investment in its late-stage pipeline and strengthened its balance sheet. Net loss was $78.7 million, or ($1.18) per share, compared to $53.8 million, or ($0.81), a year earlier, driven mainly by higher barzolvolimab clinical and manufacturing costs.
Cash, cash equivalents and marketable securities were $451.5 million as of March 31, 2026. In April, Celldex closed a follow-on underwritten public offering of 11,896,750 shares, generating $345.0 million in gross proceeds and approximately $323.9 million in net proceeds, which management believes will fund operations through 2028.
Operationally, enrollment in the Phase 3 chronic spontaneous urticaria barzolvolimab program (EMBARQ-CSU1 and CSU2) was completed six months ahead of guidance, with 1,939 patients enrolled across 43 countries. Multiple additional barzolvolimab Phase 2 and 3 studies, and the CDX-622 bispecific program, are progressing with several data readouts expected in 2026 and a planned BLA filing for barzolvolimab in 2027.
Celldex Therapeutics entered an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share. The company expects gross proceeds of about $300 million and net proceeds of approximately $282 million, before any exercise of the underwriters’ option.
The underwriters have a 30-day option to buy up to an additional 1,551,750 shares at the same price, and the deal is expected to close on or about April 6, 2026, subject to customary conditions. Celldex plans to use the net proceeds, together with existing cash and investments, to support potential commercial launch of barzolvolimab for CSU in the United States if approved, further clinical and preclinical development of its pipeline, expansion of its bispecific antibody platform, additional pipeline programs, and general corporate purposes.
Celldex Therapeutics reported wider losses for the fourth quarter and full year 2025 as it accelerated investment in its immunology pipeline, led by barzolvolimab in chronic urticarias. Fourth quarter revenue was $0.1 million, while research and development expenses rose to $75.3 million and general and administrative costs to $11.9 million.
The company posted a fourth quarter net loss of $81.3 million, or ($1.22) per share, and a full-year 2025 net loss of $258.8 million, or ($3.90) per share. Cash, cash equivalents and marketable securities were $518.6 million as of December 31, 2025, and Celldex expects this to fund operations through 2027.
Operationally, Celldex completed enrollment in both Phase 3 chronic spontaneous urticaria studies six months ahead of guidance, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Enrollment also finished in Phase 2 prurigo nodularis and atopic dermatitis trials, and the company advanced its bispecific antibody CDX-622 with ongoing Phase 1 studies, setting up multiple key data readouts in 2026.
Celldex Therapeutics (CLDX) reported that it furnished a press release announcing its third‑quarter 2025 financial results. The company disclosed this under Item 2.02 and attached the full press release as Exhibit 99.1, which is incorporated by reference.
The company stated the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
Celldex Therapeutics filed a Form 8-K to report that, on August 19, 2025, it issued a press release with results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The company attached this press release as Exhibit 99.1 and incorporated it by reference, making the clinical trial outcome an official part of its public disclosures.